Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Sorbonnelaan 16, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.
J Control Release. 2011 Jul 15;153(1):93-102. doi: 10.1016/j.jconrel.2011.06.003.
The aim of this study was to develop poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate] (mPEG-b-p(HPMAm-Lac(n))) core-crosslinked thermosensitive biodegradable polymeric micelles suitable for active tumor targeting, by coupling the anti-EGFR (epidermal growth factor receptor) EGa1 nanobody to their surface. To this end, PEG was functionalized with N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) to yield a PDP-PEG-b-p(HPMAm-Lac(n)) block copolymer. Micelles composed of 80% mPEG-b-p(HPMAm-Lac(n)) and 20% PDP-PEG-b-p(HPMAm-Lac(n)) were prepared and lysozyme (as a model protein) was modified with N-succinimidyl-S-acetylthioacetate, deprotected with hydroxylamine hydrochloride and subsequently coupled to the micellar surface. The micellar conjugates were characterized using SDS-PAGE and gel permeation chromatography (GPC). Using the knowledge obtained with lysozyme conjugation, the EGa1 nanobody was coupled to mPEG/PDP-PEG micelles and the conjugation was successful as demonstrated by western blot and dot blot analysis. Rhodamine labeled EGa1-micelles showed substantially higher binding as well as uptake by EGFR over-expressing cancer cells (A431 and UM-SCC-14C) than untargeted rhodamine labeled micelles. Interestingly, no binding of the nanobody micelles was observed to EGFR negative cells (3T3) as well as to14C cells in the presence of an excess of free nanobody. This demonstrates that the binding of the nanobody micelles is indeed by interaction with the EGF receptor. In conclusion, EGa1 decorated (mPEG/PDP-PEG)-b-(pHPMAm-Lac(n)) polymeric micelles are highly promising systems for active drug targeting.
这项研究的目的是通过将抗 EGFR(表皮生长因子受体)EGa1 纳米抗体偶联到其表面,开发出适用于主动肿瘤靶向的聚乙二醇-b-聚[N-(2-羟丙基)甲基丙烯酰胺-乳酸](mPEG-b-p(HPMAm-Lac(n)))核交联热敏生物降解聚合物胶束。为此,将 PEG 用 N-琥珀酰亚胺基 3-(2-吡啶基二硫代)丙酸酯(SPDP)功能化,得到 PDP-PEG-b-p(HPMAm-Lac(n))嵌段共聚物。制备了由 80% mPEG-b-p(HPMAm-Lac(n))和 20% PDP-PEG-b-p(HPMAm-Lac(n))组成的胶束,并使用 N-琥珀酰亚胺基-S-乙酰硫代乙酸酯修饰溶菌酶(作为模型蛋白),用盐酸羟胺脱保护,随后偶联到胶束表面。使用 SDS-PAGE 和凝胶渗透色谱(GPC)对胶束缀合物进行了表征。利用与溶菌酶缀合获得的知识,将 EGa1 纳米抗体偶联到 mPEG/PDP-PEG 胶束上,并且如 Western blot 和点印迹分析所示,缀合是成功的。与未靶向的罗丹明标记胶束相比,罗丹明标记的 EGa1-胶束显示出对 EGFR 过表达癌细胞(A431 和 UM-SCC-14C)的结合以及摄取显著增加。有趣的是,在存在过量游离纳米抗体的情况下,纳米抗体胶束对 EGFR 阴性细胞(3T3)以及 14C 细胞没有结合。这表明纳米抗体胶束的结合确实是通过与表皮生长因子受体的相互作用。总之,EGa1 修饰的(mPEG/PDP-PEG)-b-(pHPMAm-Lac(n))聚合物胶束是用于主动药物靶向的很有前途的系统。